The Online Resource for
the Mesenchymal Cell Research Community



Sign up today to save time and keep current by receiving free, weekly science newsletters delivered directly to your inbox!
  • “Thank you so much for your email and your great newsletters. My team and I really enjoy them, and I cover your “MSC news” in our group meeting each Monday.”

    – Jan Nolta, PhD
    Professor, UC Davis School of Medicine

  • “I have found these newsletters to be very valuable resources.”

    – Dean Yamaguchi, MD, PhD
    Associate Chief of Staff
    VA Greater Los Angeles Healthcare System

  • “I really enjoy your newsletters and look forward to receiving them.”

    – Kathryn Futrega, B.Sc
    PhD Student
    Queensland University of Technology

  • “I often look forward to the weekly summaries from Connexon.”

    – Kristopher Lofgren, PhD
    Boston Children’s Hospital

  • “Great newsletter, especially like the weekly summary of articles in my field in my inbox so I don’t have to go looking for them.”

    – Jennifer Adair, PhD, Fred Hutchinson Cancer Research Center and University of Washington

  • “I inadvertently got signed up for the newsletter. But because I found it so useful and informative, I have remained subscribed and actually recommended it to others.”

    – Gregory Weber, PhD
    Rutgers, The State University of New Jersey


About Mesenchymal Cell News


Mesenchymal Cell News is an integral component of the Connexon Creative newsletter library. Recognizing the need to expand our newsletter spectrum to cover the latest advances in the field of regenerative medicine and tissue engineering, we launched Mesenchymal Cell News in 2009 to facilitate the progress and communication of mesenchymal stem cell research across the globe. With more than 200 issues to date, Mesenchymal Cell News provides researchers with a reliable summary of mesenchymal cell publications and research news delivered to their inbox weekly. We are proud to provide this valuable service that keeps the global scientific community informed by compiling recent updates from all areas of the mesenchymal stem cell field, from research to business and regulatory affairs. We save scientists time while keeping them current.


Our editorial team is committed to ensuring that the publications and press releases featured in Mesenchymal Cell News are current, relevant and from reputable and reliable sources. The research papers and review articles featured in Mesenchymal Cell News cover topics such as the isolation, identification and culturing conditions of mesenchymal stem cells, as well as their cellular characterization, behavior and differentiation capacities. We also include content that focuses on identifying tissue sources of mesenchymal stem cells and their potential therapeutic applications in regenerative medicine and cellular therapies. The Industry and Science News sections of the newsletter highlight press releases from key biotech and pharmaceutical companies announcing mesenchymal stem cell treatment trials, as well as awards and funding opportunities. We also keep the mesenchymal stem cell research community engaged by posting relevant upcoming conferences, symposia, training courses and jobs in the field.


With more than 3,000 international subscribers, it is evident that Mesenchymal Cell News has become a highly valued resource for keeping current with the latest science news in the field. Our audience ranges from researchers and students in academia to medical professionals from hospital and clinical settings, as well as experts in the biotech and pharmaceutical industries specializing in regenerative medicine and mesenchymal stem cell treatments. In addition to the weekly newsletter, we also post interesting, relevant scientific content to the @MesenchymalCell Twitter feed daily. Finally, we encourage our readers to submit their recently published research and review articles, press releases, job postings, and event listings for possible inclusion in an upcoming issue of Mesenchymal Cell News.
Explore tools and resources for your return to the lab